BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Fintel reports that on September 4, 2024, Baird initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Outperform ...

Larimar Therapeutics Inc (LRMR) stock saw a decline, ending the day at $8.05 which represents a decrease of $-0.85 or -9.55% from the prior close of $8.9. The stock opened at $8.92 and touched a low ...

Aug. 07, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases ...

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies ...

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

As of August 26, 2024, the average one-year price target for Larimar Therapeutics is $25.50/share. The forecasts range from a low of $14.14 to a high of $37.80. The average price target represents ...

(MENAFN- GlobeNewsWire - Nasdaq) BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage ...